GLPwatch
Papers (9189)
Page 151 of 154, ranked by citation count.
- Therapeutic effects of finerenone and exenatide on diabetes-induced heart failure: A combined approach targeting inflammation and oxidative stress.
- [The renal protective effect and mechanism of liraglutide in diabetic mice induced by high-fat diet].
- Endometrial Transcriptome Changes following Short-Term Liraglutide Treatment in Infertile Women with Polycystic Ovarian Syndrome and Obesity.
- Clinical Presentation of a Child With a Novel ALMS1 Variant Associated With Alström Syndrome and Favorable Response to GLP-1 Receptor Agonist Therapy.
- Exenatide and sitagliptin: pancreatitis and pancreatic cancer. Harms on the rise.
- [Treatment of type 2 diabetes mellitus--which role do GLP-1 receptor agonists play?].
- Liraglutide subcutaneous injection for weight loss: where does it fit?
- Sintilimab-related fulminant autoimmune diabetes mellitus manifesting as diabetic ketoacidosis and rare insulin resistance: A case report and literature review.
- [Exenatide promotes cholesterol efflux in pancreatic tissue of obese diabetic rats].
- The effect of liraglutide, a GLP-1 analog, on indomethacin-induced gastric ulcers in diabetic rats.
- Unimolecular GLP-1/Apelin Hybrid Peptides Cause Prominent Appetite Suppression, as Well as Enhancing Insulin Secretion, Beta-Cell Survival and Glycaemic Regulation.
- The effect of exenatide on fasting bile acids in newly diagnosed type 2 diabetes mellitus patients, a pilot study.
- [Cardiovascular effects of liraglutide therapy in patients with type 2 diabetes : Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER)].
- Insulin degludec/liraglutide (Xultophy 100/3.6) for type 2 diabetes.
- Novo Nordisk pays $58.7m to settle claims of mis-selling liraglutide.
- [Clinical application of exenatide in Japanese patients with type 2 diabetes mellitus].
- Exendin-4 enhances GLP-1 signaling and reduces anxiety-like behaviors in male heroin withdrawal mice.
- Effect of liraglutide on depressive symptoms in overweight or obese patients with type 2 diabetes: protocol for a pilot randomized controlled trial.
- [Sequential treatment with insulin glargine and metformin, and exenatide in a patient with newly diagnosed type-2 diabetes].
- The role of vasopressin deficiency in the fluid intake suppression hyper-responsivity to central glucagon-like peptide-1 in the Brattleboro rat.
- [A case of an elderly diabetic patient with dementia effectively treated with weekly exenatide].
- Features of binge eating disorder in obese or overweight individuals with stable bipolar disorder participating in a weight loss trial - a post hoc analysis.
- Glucagon-like peptide 1 agonists for type 2 diabetes, weight loss, or both?
- [Impact of anti-diabetic therapy based on glucagon-like peptide-1 receptor agonists on the cardiovascular risk of patients with type 2 diabetes mellitus].
- [Effect of byetta on renal osmoregulatory function in patients with diabetes mellitus].
- [Comparison of therapeutic effect of metformin hydrochloride/vildagliptin and liraglutide on type 2 diabetes mellitus in obese patients].
- Diabetic ketoacidosis induced by liraglutide overdose for weight loss in a type 2 diabetes patient: A case report.
- [A personalized, evidence-based approach to obesity therapy using clinical algorithms: semaglutide or tirzepatide].
- Real-World Cardiovascular Outcomes of Obesity Treatment With Tirzepatide Versus Semaglutide in Non-Diabetic Adults.
- LEAN mass Preservation with Resistance Exercise and Protein during semaglutide and tirzepatide therapy (LEAN-PREP study): a protocol for a randomised controlled trial.
- Cardiorenal outcomes of weight loss interventions in people with CKD and type 2 diabetes.
- Current clinical application of incretin therapy for obesity management.
- Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown.
- Glycemic, renal, and graft outcomes with dulaglutide versus multiple daily insulin therapy after kidney transplantation in type 2 diabetes.
- Response by Wiberg et al to Letter Regarding Article, "Neuroprotective Effects of the Glucagon-Like Peptide-1 Analog Exenatide After Out-of-Hospital Cardiac Arrest: A Randomized Controlled Trial".
- Bariatric surgery and semaglutide in a youth with juvenile Huntington disease and severe obesity: a case report.
- Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Psychological Well-Being and Depressive Symptoms: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
- Community Pharmacists' Knowledge and Counseling Competence on GLP-1 Receptor Agonists in Obesity and Type 2 Diabetes Care in Türkiye: A Cross-Sectional Study.
- Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight.
- Efficacy comparison of dapagliflozin combined with liraglutide versus monotherapy in obese patients with heart failure.
- GLP1R and OCT1 variants modulate semaglutide and metformin response in type 2 diabetes.
- Impact of Liraglutide 3.0 mg on Metabolic Dysfunction-Associated Steatotic Liver Disease in Individuals with Obesity: A Real-World Study.
- Effects of Liraglutide on Mitigation of Hearing Loss After Repeated Blast Exposures: A Summary of Studies in Animal Model of Chinchilla.
- NEW FOR YOU! These innovative products aim to help make diabetes self-management easier.
- Safety of iGlarLixi in Japanese People with Type 2 Diabetes: A Post-marketing Database Study.
- Therapeutic potential of liraglutide in rheumatoid arthritis: Modulation of inflammation, apoptosis, and metabolic dysfunction in a rat model.
- Liraglutide enhances bone regeneration in a critical-size calvarial defect model in male rats: A comparative study with autogenous grafts, allografts, and xenografts.
- Comparison of pharmacotherapies for obesity with sleeve gastrectomy: a network meta-analysis and systematic review.
- Cardio-kidney-metabolic protective effects of semaglutide across the spectrum of chronic kidney disease.
- Glucagon-like peptide-1 receptor agonist in large vessel occlusion treated by reperfusion therapy-a phase 2 randomized trial.
- COMBINE 2 is better than one: shaping the future of therapeutics in inadequately controlled type 2 diabetes.
- Amycretin in obesity: Mechanisms, clinical efficacy, and future perspectives.
- Major Adverse Cardiovascular Event Outcomes in Patients With Obesity and Type 2 Diabetes Undergoing Medical Weight Management.
- Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial (Diabetes Metab J 2023;47:668-81).
- Renoprotective effect of liraglutide on diabetic nephropathy by modulation of Krüppel-like transcription factor 5 expression in rats.
- Repeated semaglutide treatment attenuates cocaine-vs-food choice in male and female rats.
- Fabrication and Preclinical Evaluation of Hyaluronic Acid/Aminoclay Nanocomposite Microneedles for Noninvasive Delivery of Semaglutide in Anti-Obesity Therapy.
- Oral delivery of liraglutide using CPP/hyaluronic acid-modified mesoporous silica nanoparticles: A virus-inspired strategy for intestinal absorption.
- Combination metformin and liraglutide in PCOS: clinical efficacy in women and preclinical insights from gut microbiome modulation in rats.
- The Role of Glucagon-Like Peptide-1 Receptor Agonists in Post ST-Segment Elevation Myocardial Infarction Care: A Scoping Review.